About SenzaGen ABSenzaGen AB is a privately owned Biotech-company, providing methods for assessment of immunotoxicological properties of chemical compounds and mixtures. Continuous R&D activities aims to broaden the application domain of provided services, and the company have close connections to immunological and toxicological researchers at Lund University, Sweden.
CEO: Anki Malmborg Hager
CSO: Malin Lindstedt
Tweets by SenzaGen
11 articles with SenzaGen AB
Companies from across the globe provide updates to their pipelines and businesses, with news from BioNTech, Mologic, Akcea, RedHill, and more.
SenzaGen has been notified by the European Center for the Validation of Alternative Methods (ECVAM) authority that due to time constrains their scientific committee (ESAC) will not be able to evaluate tests in the category ”Test Guidelines on Health Effects”, to which GARDskin belongs, this year.
SenzaGen announced today that the company will launch GARDair, the first in vitro test for airway allergies at ESTIV2018, the 20th International Congress on In Vitro Toxicology.
SenzaGen (Nasdaq First North: SENZA) announces today that the Company is now expanding its market focus to the medical device market.
SenzaGen's Final Validation Report for the Animal-free Allergy Test GARDpotency™ has Been Submitted to the Regulatory Authorities
SenzaGen announces that the company has submitted the official validation report for GARDpotency™ to the relevant regulatory authorities as a complement to the validation of GARDskin™.
Under the terms of the agreement, Eurofins BPT Munich will immediately include GARDskin and the add on test GARDpotency as a leading diagnostic tool in its chemical safety testing services to clients in the cosmetic, chemical and pharmaceutical industries worldwide.